Formycon AG

Formycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange

Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D

Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)

FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)

Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases

Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna

Formycon reports a strong first half-year with multiple milestones achieved

Formycon invites to conference call on 2024 half-year results and announces participation in international investor conferences

Formycon AG increases its outlook for the 2024 fiscal year

Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206

Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 (Ustekinumab), a biosimilar candidate to Stelara®

Stelara® Biosimilar Candidate FYB202 (Ustekinumab) receives positive CHMP opinion from EMA

Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)

FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)

Formycon reports on the results of the Annual General Meeting

Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda

MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region

Formycon reports on successful operating business and financial figures for the first quarter of 2024

Formycon invites to the Annual General Meeting on June 12, 2024 in Munich

Formycon hosts conference call on the results of the first quarter 2024

Formycon AG: Dr. Marc Mikulcik, buy

Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance

Formycon AG: Dr. Stefan Glombitza, buy

Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024

Convincing overall performance – Formycon reports preliminary results for the financial year 2023 and exceeds forecast

Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year

Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)

Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada

FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region

Gedeon Richter becomes strategic investor of Formycon via equity investment